Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers

Details for Australian Patent Application No. 2011224186 (hide)

Owner Merrimack Pharmaceuticals, Inc.

Inventors Moyo, Victor; Garcia, Gabriela

Agent Shelston IP

Pub. Number AU-A-2011224186

PCT Pub. Number WO2011/112953

Priority 61/312,895 11.03.10 US

Filing date 11 March 2011

Wipo publication date 15 September 2011

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 31/337 - having four-membered rings, e.g. taxol

A61K 31/517 - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 39/00 Medicinal preparations containing antigens or antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 Antineoplastic agents

C07K 16/30 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/32 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

13 September 2012 PCT application entered the National Phase

  PCT publication WO2011/112953 Priority application(s): WO2011/112953

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011224188-Bluetongue virus recombinant vaccines and uses thereof

2011224184-System and method for publishing synthesized data to facilitate providing information as a service